Investor Relations

Financial calendar


 

Subscribe to calendar

Latest press releases

ExpreS2ion announces financial results for the fourth quarter of 2024

Hørsholm, Denmark, 6 February 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion to Present in Upcoming Investor and Scientific Events

Hørsholm, Denmark, 9 January 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming events: PepTalk – the Annual Protein Science and Production Week in San Diego, USA, and an Institutional Investor Seminar hosted by HC Andersen Capital in Copenhagen, Denmark.

Read more

Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine

Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the new publication in The Lancet Infectious Diseases titled “Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children”. The article is based on a…

Read more

Latest presentations

2024 Q4 and Full-Year
Report Webcast

6 February 2025

Stora Aktiedagarna
Stockholm

27 November 2024

Biostock
Life Science Summit

21 November 2024